AMPE News and Press, Ampio Pharmaceuticals Inc. From 05/10/21

Ampio Pharmaceuticals Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial (AP-018) An estimated 3 to 10 million patients in the USA exhibit debilitating symptoms of Post-Acute Sequelae of SARS-CoV-2 PR Newswire ENGLEWOOD, Colo. , ...

Ampio Pharmaceuticals, Inc. (AMPE) Q1 2021 Earnings Conference Call May 5, 2021 4:30 PM ET Company Participants Dan Stokely - Chief Financial Officer Mike Macaluso - Chairman and Chief Executive Officer Dr. David Bar-Or - Director and Founder Holli Cherevka - Chief Operating Officer Conferenc...

Ampio Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update Progress achieved across therapeutic platform, including in the AP-013 Phase III trial of Ampion™ in Osteoarthritis of the Knee (OAK) Initiated two Phase II trials ut...

Ampio Pharmaceuticals ([[AMPE]] +4.8%) has revealed positive results from its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress due to COVID-19.All patients in the study have now completed treatment, including a follow-up at Day 28 after treatment.The stu...

Ampion™ Reduces All-cause Mortality in COVID-19 Respiratory Distress by Nearly 80% - All-cause mortality in patients treated using Standard of Care (SOC) was 24%, but only 5% in the group treated with Ampion (a 78% reduction) - The AP-014 Phase I trial of inhaled Ampi...

Ampio Pharmaceuticals Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19 - Positive FDA response provides guidance on multiple pathways forward on paused Phase III trial in osteoarthritis of the knee (OAK) - Phase I trial of inhaled Ampio...

Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Business Update PR Newswire ENGLEWOOD, Colo. , April 21, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company foc...

Research Shows Ampion™ Gene Regulation Mimics the Anti-Inflammatory Effects of Steroids, but without Adverse Effects PR Newswire ENGLEWOOD, Colo. , April 19, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company ...

Ampio Pharmaceuticals ([[AMPE]]) announces results of a pre-clinical study demonstrating that Ampion inhibits an important pro-inflammatory pathway in the types of immune cells implicated in COVID-19 and Lupus Nephritis, a condition that causes inflammation of the kidney.The aim of ...

Ampio Pharmaceuticals' Study Shows Ampion Inhibits a Key Inflammatory Pathway in COVID-19 and Lupus Nephritis Laboratory results suggest Ampion's suitability for addressing kidney diseases and provides further evidence it is a platform biologic for treatment of inflammatory and ...